Vaccination against chickenpox causes a varicella-like rash in up to 5% of healthy children and 50% of children with leukemia. The vaccine may establish latency and reactivate to cause herpes zoster, albeit more rarely than wild-type virus. All vaccine preparations are composed of a mixture of varicella-zoster virus strains that show genotypic variation at several loci. Immunization against chickenpox with vaccine Oka (vOka), the attenuated vaccine strain derived from parental Oka (pOka), a wild-type (wt) Japanese varicella-zoster virus (VZV), is widely performed in the United States, and the vaccine is licensed for use for VZV-seronegative health care workers in the United Kingdom. Vaccination causes seroconversion to VZV in 95% of healthy children, preventing 85% of varicella infections and 197% of severe varicella infections [1] . The vaccine is extremely safe. Since its licensure in the United States, 140 million doses of the Merck vaccine have been distributed, and there have been only 5 recognized severe adverse reactions associated with the vaccine, none of which was fatal [2] [3] [4] [5] . Nonetheless, vac-
cine-associated problems can occur; the most common of these problems is a varicella-like rash that occurs in ∼5% of healthy children, 10% of healthy adults, and up to 50% of children with acute leukemia that is in remission [1] . Vaccine-associated rashes generally are mild in healthy vaccine recipients, involving !50 lesions, compared with the average of 300 lesions that occur in wt virus-associated rashes [1] . The vaccine virus is able to establish latency, as evidenced by its ability to reactivate to cause herpes zoster [5] . To examine the association between the virus in the vaccine preparation and viruses that cause rash, we compared the DNA sequence of viruses from 12 vaccine-associated varicella rashes and from 3 vaccine-associated zoster rashes with the DNA sequence of the original Oka vaccine strain.
Three formulations of the vOka vaccine (i.e., Biken, Merck, and SmithKline Beecham Biologicals) are commercially available. The DNA sequence of the Biken vOka virus reveals differences at 42 loci, compared with the Japanese parental strain from which the Biken vOka virus was derived [6] . At 11 loci, complete substitution of the wt virus nucleotide has occurred. The remaining 31 loci (including 15 loci at which an amino acid change occurs) show a mixture of both vaccine virus and wt virus nucleotides, after direct sequencing of whole vaccine DNA. Thus, the Biken vaccine appears to be a mixture of virus strains. Sequencing of subcloned fragments from VZV gene 62 has also confirmed the presence of at least 9 viral variants in the Biken vaccine [7] .
We sequenced 35 of the putative variant loci reported by Gomi et al. [6] , in 2 batches of the Merck vaccine, and we confirmed that 25 of the loci showed variation and that 21 appeared to be a mixture of virus strains on the sequence trace. Thus, the Merck vaccine, like the Biken vaccine, is composed of a mixture of genotypically distinct strains. In addition, we identified, in the Merck vaccine, 2 new nonsynonymous mutations (at positions 87815 and 105724) that were not present in the Biken vaccine (figure 1). We cultured viruses sampled from single vesicles from 8 vaccine-associated rashes and 3 cases of herpes zoster that occurred after immunization of children who had leukemia, as well as from 4 healthy adults (table 1) . Nine lots of Merck's prelicensure vaccine strains (A-I) had been administered to these 12 individuals. DNA sequence was obtained from the 35 published loci, as well as from 5 new loci that we identified (figure 1), and the presence of vaccine-associated sequence variants in all 15 rash-associated viruses confirmed that they were of vaccine origin (figure 1) [8] . The 2 new nonsynonymous mutations were also found in the rash-associated viruses, and 5 additional mutations (1 of which was nonsynonymous and 4 of which were synonymous) were identified. Additional typing was performed at loci that differ between the known American strains and the Japanese strain that was the progenitor of the vaccine [9] . Because the patients were resident in the United States, recombination between vaccine and virus in the host would be expected to generate a haplotype with a mixture of American and Japanese variants [10] . However, by use of markers that previously have been shown to detect recombinant genotypes, no such recombination was found ( figure 1 and data not shown) . No evidence of mixed vaccine virus and wt virus nucleotides was found at any of the 35 loci sequenced in the 15 rash-associated viruses. In 3 of the 15 cases, this result was confirmed by the limiting dilution method [11] . Twenty genomes of each virus were individually amplified using a polymerase chain reaction primer pair spanning 4 polymorphic loci between 105331 and 105724 in ORF62. In all 3 cases, there was identity between individual viral genomes from the same rash (data not shown).
The results show that virus sampled from vaccine-associated rashes, including cases of herpes zoster, are, genotypically, single strains, despite the mixture of strains present in the original vaccine. These results were obtained using low-passage (number of passages, !5) tissue culture samples obtained from individual vesicles. More recent data have confirmed the clonality of rash-associated viruses sampled directly from vesicle fluids (J.B., unpublished data), excluding the possibility of in vitro selection. After immunization, vOka virus replicates locally, infects peripheral blood mononuclear cells, and is carried to distant sites, including the skin [12] . Clonal selection of vaccine variants could occur at any of these stages. At present, we are unable to distinguish between these possibilities. Future experiments to answer these questions will include sampling of several different vesicles from the same rash, sampling of peripheral blood mononuclear cells during the viremic phase, and sampling performed at the inoculation site.
No association between rash severity and particular polymorphisms in the rash-associated viruses, or between rash severity and the vaccine lot used, was detected (table 1) . However, 2 nonsynonymous polymorphisms (at position 90535 in ORF52, a homologue of HSV UL8, which codes for the helicase protein, and at position 107797 in ORF62, a homologue of the HSV ICP4, which codes for IE62, the intermediate-early transactivating protein product of VZV gene 62), although they were a mixture of virus strains in the vaccine, were wt viruses in all the rash-associated viruses (figure 1). Neither locus is associated with a known functional domain. Six of the rash viruses, herpes zoster 3, and rashes 1-4 and 8, appear to be clonally related, sharing between 14 and 16 of the 29 informative polymorphic loci, including the proline substitution at position 1136 (figure 1). The 6 rash-associated viruses derive from only 3 vaccine batches. Thus, the similarities in sequence that were observed might reflect characteristics shared by the restricted number of viral seed lots from which they derive (table 1) . Sequencing of more rash-associated viruses is now needed to establish whether any of the shared alleles identified are chance findings or whether, during the process of rash formation, selection at certain loci occurs.
Two nonsynonymous vaccine mutations (at positions 106262 and 107252 in ORF62) were present in the vaccine and were conserved in all the rashes due to vaccine. The nucleotide substitution at position 106262 codes for a change in the protein sequence, at position 958, from arginine in pOka to glycine in vOka, and the substitution at 107252 changes the protein sequence, at position 628, from serine in pOka to glycine in vOka. It previously has been noted that the glycine at position 958 is shared with the laboratory-adapted VZV strain Ellen, which, like vOka, is attenuated in the SCID-hu mouse model [13] . The substitution at position 628 lies close to the main DNAbinding domain of the IE62 protein [14] . It is possible that these 2 conserved vaccine substitutions are important for the attenuated phenotype of vaccine virus (figure 1). Apart from a synonymous mutation at position 89734 in ORF51, which codes for the origin binding protein and which was present in the herpes zoster rashes only, there was no obvious difference between the genotype of the 12 varicella-like rashes and the 3 herpes zoster rashes (figure 1).
Our data show that the Merck vaccine preparation, like the Biken vaccine, is a mixture of related strains, which are mutated at several loci, compared with the pOka virus from which it derived. After immunization with this mixture of VZV vaccine viruses, selection of viral clones occurs at or before the formation of vesicles. These findings provide us with a model with which to examine the influence of viral variants on the pathogenesis of rash formation associated with VZV infection. Thus, it should be possible to determine, from detailed studies of immunized individuals, whether there are intrinsic viral properties that influence local replication in the skin, spread of viremia, and subsequent vesicle formation.
We currently are unable to determine whether the viral variants reported in the present study are more likely to cause rash or whether their isolation from vaccine-associated rashes is serendipitous. Sequence analysis of more rash-associated vaccine viruses is needed to examine further whether these variants are associated with rash or, indeed, with more serious, albeit rare, complications. Two coding vaccine mutations were conserved in all 15 of the rash-associated vaccine viruses sequenced and may be important for vaccine virus attenuation.
